Menu Search
Equities

Pharmena SA

PHR:WSE

Pharmena SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)4.97
  • Today's Change-0.07 / -1.39%
  • Shares traded201.00
  • 1 Year change-16.61%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Pharmena SA has grown net income from a loss of 1.57m to a gain of 28.94m despite flat revenues.
Gross margin27.15%
Net profit margin9,958.08%
Operating margin11,369.76%
Return on assets88.31%
Return on equity1,109.11%
Return on investment1,064.19%
More ▼

Cash flow in PLNView more

In 2023, Pharmena SA increased its cash reserves by 1,296.80%, or 20.65m. The company earned 33.03m from its operations for a Cash Flow Margin of 11,047.49%. In addition the company used 3.13m on investing activities and also paid 9.26m in financing cash flows.
Cash flow per share2.61
Price/Cash flow per share1.93
Book value per share1.11
Tangible book value per share1.09
More ▼

Balance sheet in PLNView more

Pharmena SA has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 22.24m.
Current ratio11.75
Quick ratio11.31
Total debt/total equity0.0126
Total debt/total capital0.0125
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.